![Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features | The Journal of Rheumatology Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/49/5/544/F1.large.jpg)
Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features | The Journal of Rheumatology
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis | Clinical Research Trial Listing ( Psoriatic Arthritis ) ( NCT04209205 )
![IL-17 Protein Plays an Important Role in Skin Aging, FDA Approved Therapies Available - News - Rapamycin Longevity News IL-17 Protein Plays an Important Role in Skin Aging, FDA Approved Therapies Available - News - Rapamycin Longevity News](https://www.rapamycin.news/uploads/default/original/2X/d/d70ab34877660655e1f0ed8006b163c06c288ad4.png)
IL-17 Protein Plays an Important Role in Skin Aging, FDA Approved Therapies Available - News - Rapamycin Longevity News
![MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes: Molecular Therapy - Nucleic Acids MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/e78666e7-30c5-4309-be49-efcb462d4c20/gr8_lrg.jpg)
MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes: Molecular Therapy - Nucleic Acids
![IL-17 Protein Plays an Important Role in Skin Aging, FDA Approved Therapies Available - News - Rapamycin Longevity News IL-17 Protein Plays an Important Role in Skin Aging, FDA Approved Therapies Available - News - Rapamycin Longevity News](https://www.rapamycin.news/uploads/default/original/2X/a/acedfefcf401256a49a8d36a8e5c4306d68873d2.jpeg)